EU Pharma Package: EMA with single Point of Information
Recommendation
2/3 September 2026
Copenhagen, Denmark
When “Human Error” isn’t enough: Successful Failure Investigation
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The European Medicines Agency EMA has created a webpage dedicated to the implementation of the reform of the EU pharmaceutical legislation. This new pharmaceutical legislation represents the most significant overhaul of the regulatory framework in over two decades. It aims to modernise how medicines are developed, authorised, and made available to patients across the EU.
The newly launched webpage will serve as a central repository of information for all EMA's stakeholders, providing up-to-date guidance and resources. It highlights the key benefits of the new pharmaceutical legislation and, once the new legislative text is adopted in 2026, it will offer detailed insights into the implementation process on specific technical and procedural aspects.
The webpage will cover in particular the six activity areas overseen by EMA, namely:
- Centralised procedure and committees
- Development support
- Environmental risks
- Quality and manufacturing
- Shortages
- Regulatory and legal aspects
EMA will provide details on these activity areas following the adoption of the new legislative text in 2026.
Related GMP News
17.08.2026Why Root Cause Analysis is the Key to efficient CAPA
17.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
17.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?
15.07.2026Root Cause Analysis and CAPA: Two more Warning Letters issued to Companies in Europe